Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2025 08:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim

Numab to receive first milestone payment Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical...
September 09, 2025 08:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer

HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and...
January 09, 2025 10:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
November 15, 2024 04:30 ET | Source: Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.

Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease

Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...